For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 1,697,448 | 1,265,891.5* | 1,738,751 | 1,742,594 |
| Research and development | 3,433,762 | 3,305,628.25* | 2,281,174 | 2,050,585 |
| Total operating expenses | 5,131,210 | 4,571,519.75* | 4,019,925 | 3,793,179 |
| Unrealized (loss) gain | -13,300 | -1,255* | 9,494 | -6,004 |
| Realized and accrued interest income | 146,775 | 233,814.5* | 62,266 | 103,245 |
| Total other income | 133,475 | 232,559.5* | 71,760 | 97,241 |
| Net loss | -4,997,735 | -4,338,960.25* | -3,948,165 | -3,695,938 |
| Foreign currency translation | 454 | -153.25 | - | - |
| Total other comprehensive loss | - | -153.25* | - | - |
| Comprehensive loss | -4,997,281 | -4,339,113.5 | - | - |
| Basic EPS | -1.77 | -2.803 | -6.71 | - |
| Diluted EPS | -1.77 | -2.803 | -6.71 | - |
| Basic Average Shares | 2,830,970 | 1,548,138 | 588,166 | - |
| Diluted Average Shares | 2,830,970 | 1,548,138 | 588,166 | - |
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)